• Home
  • Opinion
  • Politics
  • World
  • Business
  • Science & Tech
Tuesday, August 16, 2022
No Result
View All Result
SUBSCRIBE
The Outlooker
27 °c
Delhi
  • Home
  • Opinion
  • Politics
  • World
  • Business
  • Science & Tech
  • Home
  • Opinion
  • Politics
  • World
  • Business
  • Science & Tech
No Result
View All Result
The Outlooker
No Result
View All Result
  • National
  • Politics
  • Opinion
  • Business
  • Science
  • World
  • Health
Home Business

‘Neutral’ on Cipla, co well-placed to deliver 24% earnings CAGR

by The Outlooker Web Desk
December 15, 2020
in Business
0
1.8k
SHARES
12.9k
VIEWS
Share on FacebookShare on Twitter

It had reached a similar agreement with Alvogen on g-Revlimid sales in the US.

Cipla and Celgene (innovator) have reached an agreement to settle the litigation pertaining to g-Revlimid in the US. According to the settlement, Cipla can begin selling g-Revlimid in the US sometime after March 2022.
Considering other settlements, limited build-up of sales over FY23-26E, and unlimited quantities of g-Revlimid by Cipla post Jan-26E, there could be a potential NPV addition of `40 per share from this opportunity. We await clarity on further details of the agreement.

The extended benefit of operational cost savings in DF, ramp-up in albuterol sulfate sales, and increased business for Covid-19 products, Cipla is well-placed to deliver 24% earnings CAGR over FY20-23E. We maintain our ‘neutral’ rating as the valuation factors potential upside in earnings over the medium-term

According to the settlement terms, Cipla will be allowed to sell volume-limited quantities of g-Revlimid in the US beginning some time in FY23. Post Jan-26, Celgene has agreed to provide Cipla with a licence to its patent required to manufacture and sell an unlimited quantity of g-Revlimid in the US.

The innovator had settled cases with NTCPH, Alvogen and DRRD on g- Revlimid previously. According to the settlement with NTCPH, it is allowed to sell mid- to single-digit volume share of total g-Revlimid sold in the US in the first year of entry. The volume limitation would gradually rise each year until March 25, when it is allowed to sell up to one-third of all g-Revlimid sold in the US by volume.

It had reached a similar agreement with Alvogen on g-Revlimid sales in the US. However, the maximum volume share of g-Revlimid that Alvogen is allowed to sell in the final year of the settlement is restricted to single-digits. A similar agreement was reached recently with DRRD, too. However, the amount that DRRD is allowed to sell has not been disclosed.

SUNP, LPC, ARBP, CDH, Mylan, Apotex, and Hetero Drugs are other companies currently in patent challenges with innovator on g-Revlimid. g-Revlimid (Lenalidomide) is used to treat multiple myeloma in adults. The drug is available as orally administered capsules. Patents on g-Revlimid expire on April 27, 2027. g-Revlimid’s sales in the US stood at $7.3 billion in CY19, up 13% YoY. Its sales in 9MCY20 stood at $6.1 billion.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

The Outlooker is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

The Outlooker Web Desk

The Outlooker Web Desk

Next Post
India’s COVID-19 Cases Crosses 94 Lakh-Mark

India's Covid-19 Tally Reaches 98,84,100 With 27,071 New Cases

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Meghalaya High Court Rejects Journalist Patricia Mukhim’s Plea Against Criminal Case
National

138 Judicial Appointments So Far In 2022: Law Ministry

August 15, 2022
AAP’s Raghav Chadha’s Special Video Message On Independence Day
National

AAP’s Raghav Chadha’s Special Video Message On Independence Day

August 15, 2022
India ranked 11th in ISSF’s World Soft Power Index 2022
National

India ranked 11th in ISSF’s World Soft Power Index 2022

August 15, 2022
For Threat Calls To Mukesh Ambani, Man Detained By Mumbai Police
National

For Threat Calls To Mukesh Ambani, Man Detained By Mumbai Police

August 15, 2022

Connect with us

No Result
View All Result

Archives

  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020

Category

  • Artistic
  • Business
  • Crypto
  • Design
  • Entertainment
  • Fashion
  • featured
  • Food
  • Gaming
  • Health
  • Human
  • Lifestyle
  • Movie
  • Music
  • National
  • Opinion
  • Politics
  • Science
  • Spaces
  • Sports
  • Tech
  • Travel
  • Uncategorized
  • World

Recent Posts

  • 138 Judicial Appointments So Far In 2022: Law Ministry
  • AAP’s Raghav Chadha’s Special Video Message On Independence Day
  • India ranked 11th in ISSF’s World Soft Power Index 2022

About Us

The Outlooker

The Outlooker is your source of authentic, hand-picked news, stories, analysis from India & the World.

  • Terms Of Service
  • Privacy Policy
  • About us
  • Submit your story
  • Contact

© 2019-2021 The Outlooker. All rights reserved.

No Result
View All Result
  • Home
  • Politics
  • World
  • Business
  • Science
  • National
  • Entertainment
  • Gaming
  • Movie
  • Music
  • Sports
  • Fashion
  • Lifestyle
  • Travel
  • Tech
  • Health
  • Food

© 2019-2021 The Outlooker. All rights reserved.